SLDB — Solid Biosciences Inc. Stock Price, Chart & AI Report

Positive Dec 16, 2025 • 21:51 UTC GlobeNewswire Inc. • Solid Biosciences Inc.

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

U.S. Department of Health and Human Services added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, which is expected to accelerate early detection and improve patient outcomes.

SLDB Duchenne muscular dystrophy newborn screening gene therapy rare disease

Sentiment note

Company is actively supporting Duchenne research, advocating for newborn screening, and developing innovative gene therapy treatments, demonstrating proactive commitment to addressing the disease

Positive Dec 1, 2025 • 13:00 UTC GlobeNewswire Inc. • Solid Biosciences Inc.

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, a dual-route gene therapy targeting Friedreich's ataxia. The therapy aims to restore frataxin protein levels and address neurologic, cardiac, and systemic disease manifestations.

SLDB gene therapy Friedreich's ataxia FDA designation rare disease

Sentiment note

Company received important FDA designations (Rare Pediatric Disease and Fast Track) for its investigational gene therapy, indicating promising progress in developing a treatment for a rare genetic disorder

Positive Nov 17, 2025 • 13:00 UTC GlobeNewswire Inc. • Solid Biosciences Inc.

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Solid Biosciences has signed a non-exclusive worldwide license agreement with Andelyn Biosciences to provide access to its proprietary AAV-SLB101 gene therapy capsid, expanding collaborative efforts to over 30 agreements.

SLDB gene therapy licensing AAV capsid neuromuscular diseases CDMO

Sentiment note

Company is expanding collaborative efforts, demonstrating successful licensing of its proprietary technology and advancing gene therapy research

Positive Nov 11, 2025 • 13:00 UTC GlobeNewswire Inc. • Nicole Anderson

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences will participate in two healthcare investor conferences in November and December 2025, featuring presentations by its President/CEO and Chief Medical Officer, with live webcasts available.

SLDB JEF PIPR gene therapy neuromuscular diseases healthcare conferences investor relations

Sentiment note

Company is actively engaging with investors, showcasing its pipeline of genetic medicine candidates and demonstrating transparency through conference participation

Neutral Aug 1, 2025 • 12:00 UTC GlobeNewswire Inc. • Nicole Anderson

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences awarded 55,450 restricted stock units to four newly hired employees, with vesting over four years, under their 2024 Inducement Stock Incentive Plan.

SLDB restricted stock units gene therapy neuromuscular diseases cardiac diseases

Sentiment note

The company is making standard employee equity grants and continuing its focus on developing genetic medicines for rare diseases, indicating stable business operations

Positive Jun 5, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight

The dilated cardiomyopathy market is experiencing steady growth, driven by rising prevalence of heart failure, improved diagnostic techniques, and advancements in genetic testing. Increasing R&D investment in gene therapies and novel drug candidates is expanding treatment options.

AMGN BMY CELGR CPIX dilated cardiomyopathy heart failure cardiovascular therapies gene therapies

Sentiment note

Solid Bioscience is developing AVB-401 and SGT-601, which are novel therapies for dilated cardiomyopathy, and their anticipated launch is expected to transform the dilated cardiomyopathy market.

Positive Nov 26, 2024 • 13:00 UTC GlobeNewswire Inc. • N/A

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences, a life sciences company developing precision genetic medicines, announced its participation in two upcoming investor conferences, where the company's leadership will discuss its pipeline of gene therapy candidates for neuromuscular and cardiac diseases.

SLDB Solid Biosciences gene therapy neuromuscular diseases cardiac diseases

Sentiment note

The article highlights Solid Biosciences' participation in investor conferences, which suggests the company is actively engaging with the investment community and promoting its pipeline of gene therapy candidates for various diseases. This indicates a positive outlook for the company's business and growth prospects.

Positive Jul 15, 2024 • 08:52 UTC Investing.com • Emilio Ghigini

Rocket Lab stock downgraded by Morgan Stanley due to revised growth outlook By Investing.com - Investing.com

JPMorgan has upgraded Solid Biosciences' stock from Neutral to Overweight, citing the company's promising gene therapy pipeline and the favorable regulatory environment for its products.

SLDB Solid Biosciences gene therapy biotechnology stock upgrade

Sentiment note

JPMorgan is optimistic about Solid Biosciences' growth potential, particularly with the upcoming data release for its key pipeline product SGT-003. The firm believes the company's gene therapy portfolio and the supportive regulatory environment for rare diseases provide a favorable outlook.

Unknown Jul 1, 2024 • 20:19 UTC GlobeNewswire Inc. • Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.

SLDB Changes in company's own shares

Unknown Jun 24, 2024 • 12:09 UTC Benzinga • Avi Kapoor

This Planet Fitness Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Max Rakhlenko upgraded the rating for Planet Fitness, Inc. (NYSE:PLNT) from Hold to Buy, while raising the price target from $66 to $92. Planet Fitness shares fell 0.4% to close at $72.73 on Friday. See how other analysts view this stock. Roth MKM analyst Eric Handler upgraded Cinemark Holdings, Inc. (NYSE:CNK) from Neutral to Buy and boosted the price target from $19 to $26. Cinemark shares ...Full story available on Benzinga.com

DMRC SIRI CNK PLNT News Upgrades Markets Analyst Ratings

Unknown Jun 21, 2024 • 15:24 UTC Zacks Investment Research • Zacks Equity Research

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.

RHHBY PFE SRPT RGNX

Unknown Jun 4, 2024 • 20:00 UTC GlobeNewswire Inc. • Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units (“RSUs”) to four newly hired employees.

SLDB Product / Services Announcement